These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24462281)

  • 1. Glycaemic control in insulin requiring diabetes patients receiving exclusive enteral tube feeding in an acute hospital setting.
    Murphy PM; Moore E; Flanagan DE
    Diabetes Res Clin Pract; 2014 Mar; 103(3):426-9. PubMed ID: 24462281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.
    Kerlan V; Gouet D; Marre M; Renard É
    Ann Endocrinol (Paris); 2013 Dec; 74(5-6):487-90. PubMed ID: 23978337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K; Dornhorst A; Sreenan S
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: Analysis of real-life data from the DPV registry from Germany and Austria.
    Bohn B; Kerner W; Seufert J; Kempe HP; Jehle PM; Best F; Füchtenbusch M; Knauerhase A; Hofer M; Rosenbauer J; Holl RW;
    Diabetes Res Clin Pract; 2016 May; 115():31-8. PubMed ID: 27242120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective Evaluation of Glycemic Control With Basal-Bolus or Neutral Protamine Hagedorn Insulin Regimens in Patients Receiving Continuous Enteral Nutrition Therapy in Medicine Wards.
    Hijaze D; Szalat A
    Nutr Clin Pract; 2017 Aug; 32(4):557-562. PubMed ID: 28760108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes.
    Marre M; Pinget M; Gin H; Thivolet C; Hanaire H; Robert JJ; Fontaine P
    Diabetes Metab; 2009 Dec; 35(6):469-75. PubMed ID: 19914118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing hypoglycaemia with insulin analogues.
    Heller S
    Int J Obes Relat Metab Disord; 2002 Sep; 26 Suppl 3():S31-6. PubMed ID: 12174321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin glargine dosing before next-day surgery: comparing three strategies.
    Rosenblatt SI; Dukatz T; Jahn R; Ramsdell C; Sakharova A; Henry M; Arndt-Mutz M; Miller V; Rogers K; Balasubramaniam M
    J Clin Anesth; 2012 Dec; 24(8):610-7. PubMed ID: 23122972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycaemic control in type 2 diabetes mellitus patients undergoing major surgery: comparison of three subcutaneous insulin regimens.
    Mathur SK; Bansal A; Khan ZY
    J Indian Med Assoc; 2009 Nov; 107(11):759-61. PubMed ID: 20469779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary rates of severe hypoglycaemia in youth with type 1 diabetes: variability by insulin regimen.
    Katz ML; Volkening LK; Anderson BJ; Laffel LM
    Diabet Med; 2012 Jul; 29(7):926-32. PubMed ID: 22417321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin degludec allows for better glycaemic control with a lower risk of hypoglycaemia in patients with chronic kidney disease and type 2 diabetes.
    Dolores García de Lucas M; Avilés Bueno B; Rivas Ruiz F; Olalla Sierra J
    Diabetes Res Clin Pract; 2020 Apr; 162():108094. PubMed ID: 32113852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A UK national survey of enteral feed use in people with diabetes 2022.
    Flanagan D; Lake AK; Green M; Roberts A; Dhatariya K;
    Diabet Med; 2024 Mar; 41(3):e15216. PubMed ID: 37704415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
    Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
    Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal-bolus insulin versus sliding-scale insulin for inpatient glycaemic control: a clinical practice comparison.
    Roberts GW; Aguilar-Loza N; Esterman A; Burt MG; Stranks SN
    Med J Aust; 2012 Mar; 196(4):266-9. PubMed ID: 22409694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
    Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L; Koenen C; Weng W; Selam JL
    Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the safety of the new ultra long acting basal insulin.
    Ramachandran A; Gupta V; Kesavadev J; Kalra S
    J Assoc Physicians India; 2014 Jan; 62(1 Suppl):35-42. PubMed ID: 25330630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy.
    Hirsch IB; Buse JB; Leahy J; McGill JB; Peters A; Rodbard HW; Rubin RR; Skyler JS; Verderese CA; Riddle MC
    Diabetes Obes Metab; 2014 Mar; 16(3):206-14. PubMed ID: 23711193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do high fasting glucose levels suggest nocturnal hypoglycaemia? The Somogyi effect-more fiction than fact?
    Choudhary P; Davies C; Emery CJ; Heller SR
    Diabet Med; 2013 Aug; 30(8):914-7. PubMed ID: 23672623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.